Hyperuricemia - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H2 2016, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4, 4 and 4 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Hyperuricemia.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hyperuricemia Overview 8
Therapeutics Development 9
Pipeline Products for Hyperuricemia - Overview 9
Pipeline Products for Hyperuricemia - Comparative Analysis 10
Hyperuricemia - Therapeutics under Development by Companies 11
Hyperuricemia - Therapeutics under Investigation by Universities/Institutes 12
Hyperuricemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Hyperuricemia - Products under Development by Companies 16
Hyperuricemia - Products under Investigation by Universities/Institutes 17
Hyperuricemia - Companies Involved in Therapeutics Development 18
Allena Pharmaceuticals, Inc. 18
AstraZeneca Plc 19
CymaBay Therapeutics, Inc. 20
Jiangsu Hengrui Medicine Co., Ltd. 21
Nippon Chemiphar Co., Ltd. 22
Nobelpharma Co., Ltd. 23
Polaris Pharmaceuticals, Inc. 24
Teijin Pharma Limited 25
Hyperuricemia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(allopurinol + lesinurad) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ALLN-346 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
arhalofenate - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
febuxostat - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
JPH-367 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
NC-2500 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
NC-2700 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
pegadricase - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Pyruvic acid - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
SHR-4640 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
TMX-049 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
verinurad - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
XEN-102 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Hyperuricemia - Dormant Projects 58
Hyperuricemia - Discontinued Products 59
Hyperuricemia - Product Development Milestones 60
Featured News & Press Releases 60
Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland 60
May 23, 2016: Teijin Pharma's Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia 61
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 61
Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe 62
Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat 63
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric 64
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat 64
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 65
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea 66
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan 66
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 67
Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan 67
Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada 68
Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe 68
Mar 05, 2010: Launch by Menarini and Ipsen of Adenuric (febuxostat) in France for the treatment of chronic hyperuricemia in gout 68
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Hyperuricemia, H2 2016 9
Number of Products under Development for Hyperuricemia - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Hyperuricemia - Pipeline by Allena Pharmaceuticals, Inc., H2 2016 18
Hyperuricemia - Pipeline by AstraZeneca Plc, H2 2016 19
Hyperuricemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016 20
Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 21
Hyperuricemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 22
Hyperuricemia - Pipeline by Nobelpharma Co., Ltd., H2 2016 23
Hyperuricemia - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 24
Hyperuricemia - Pipeline by Teijin Pharma Limited, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Hyperuricemia - Dormant Projects, H2 2016 58
Hyperuricemia - Discontinued Products, H2 2016 59